Polymorphisms in the human gene for the multidrug resistance-associated protein 1 (MRP-1) and their use in diagnostic and therapeutic applications
View Patent ↗The present invention relates to a polymorphic MRP-1 polynucleotide. Moreover, the invention relates to genes or vectors comprising the polynucleotides of the invention and to a host cell genetically engineered with the polynucleotide or gene of the invention. Further, the invention relates to methods for producing molecular variant polypeptides or fragments thereof, methods for producing cells capable of expressing a molecular variant polypeptide and to a polypeptide or fragment thereof encoded by the polynucleotide or the gene of the invention or which is obtainable by the method or from the cells produced by the method of the invention. Furthermore, the invention relates to an antibody which binds specifically the polypeptide of the invention. Moreover, the invention relates to a transgenic non-human animal. The invention also relates to a solid support comprising one or a plurality of the above mentioned polynucleotides, genes, vectors, polypeptides, antibodies or host cells. Furthermore, methods of identifying a polymorphism, identifying and obtaining a pro-drug or drug or an inhibitor are also encompassed by the present invention. In addition, the invention relates to methods for producing of a pharmaceutical composition and to methods of diagnosing a disease. Further, the invention relates to a method of detection of the polynucleotide of the invention. Furthermore, comprised by the present invention are a diagnostic and a pharmaceutical composition. Even more, the invention relates to uses of the polynucleotides, genes, vectors, polypeptides or antibodies of the invention. Finally, the invention relates to a diagnostic kit.
1. A method of determining whether a human subject is at risk for drug-induced hepatic toxicity, comprising the steps of:
(a) detecting the MRP-1 genotype at a position corresponding to position 11 of SEQ ID NO:171 in the human subject; and
(b) (i) based on the detection of a homozygous (C/C) at the position corresponding to position 11 of SEQ ID NO:171 in the human subject determining that the human subject is at risk for drug-induced hepatic toxicity; or
(ii) based on the detection of a heterozygous (T/C) or homozygous (T/T) at the position corresponding to position 11 of SEQ ID NO:171 in the human subject determining that the human subject is at decreased risk for drug-induced hepatic toxicity relative to the detection of a homozygous (C/C) at said position.
2. The method of claim 1 , wherein the human subject has a disorder caused by multidrug resistance.
3. The method of claim 1 , wherein detecting the MRP-1 genotype comprises one or more techniques selected from the group consisting of PCR, ligase chain reaction, restriction digestion, direct sequencing, nucleic acid amplification techniques, and hybridization techniques.
4. An in vitro method for assessing the susceptibility of a human subject to drug-induced hepatic toxicity,
(a) detecting the MRP-1 genotype at a position corresponding to position 11 of SEQ ID NO:171 in the human subject; and
(b) (i) based on the detection of a homozygous (C/C) at the position corresponding to position 11 of SEQ ID NO:171 in the human subject determining that the human subject has an increased susceptibility to drug-induced hepatic toxicity; or
(ii) based on the detection of a heterozygous (T/C) or homozygous (T/T) at the position corresponding to position 11 of SEQ ID NO:171 in the human subject determining that the human subject has a decreased susceptibility to drug-induced hepatic toxicity relative to the detection of a homozygous (C/C) at said position wherein detecting the MRP-1 genotype comprises one or more techniques selected from the group consisting of PCR, restriction digestion, direct sequencing, nucleic acid amplification techniques, and hybridization.
5. The method of claim 1 , wherein the human subject has a disorder is associated with caused by drug-induced hepatotoxicity.